LumiraDx Limited (LMDX) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is LMDX = $2 (+9275% upside).
Financials: revenue is $254M, +221.5%/yr average growth. Net income is $449M (loss), growing at -122.9%/yr. Net profit margin is -176.5% (negative). Gross margin is -13.9% (-52 pp trend).
Balance sheet: total debt is $401M with negative equity of -$105M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.91 (strong liquidity). Debt-to-assets is 91%. Total assets: $441M.
Analyst outlook: 3 / 4 analysts rate LMDX as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 8/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
